Abaxis Inc (ABAX) 60.93 $ABAX
Medtronic's Reveal Cardiac Monitor: Key to AF Detection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:15PM CST
The incremental cost-effectiveness ratio (ICER) associated with the utilization of Medtronic's (MDT) Reveal XT ICM came well within the cost-effectiveness range supported by the United Kingdom's National Institute of Clinical Excellence.
CSII: 35.69 (+0.17), MDT: 75.26 (+0.33), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65)
Phibro Animal Health (PAHC) in Focus: Stock Jumps 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:18AM CST
Phibro Animal Health Corporation (PAHC) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
ABAX: 60.93 (+0.65), PAHC: 30.85 (+0.36)
Why Abaxis (ABAX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:34AM CST
Abaxis in the Medical Products space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
ABAX: 60.93 (+0.65)
St. Jude Medical HALO US IDE Trial Tests 15mm Heart Valves - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:13PM CST
Global medical devices company, St. Jude Medical (STJ), recently launched the HALO U.S. IDE Trial.
CSII: 35.69 (+0.17), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65), STJ: 67.48 (+0.65)
ResMed Targets Expansion in HME Market, Acquires Jaysec - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:09PM CST
Through Jaysec's acquisition, ResMed (RMD) will experience reduced administrative burden owing to the self-serve software portal specifically designed for HME providers.
CSII: 35.69 (+0.17), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65), RMD: 66.25 (+0.79)
Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 11:30AM CST
Hospira (HSP) inked a deal with Pfenex Inc. (PFNX) for the development and global commercialization of PF582, a biosimilar of Lucentis (eye treatment).
ABAX: 60.93 (+0.65), PFE: 34.64 (-0.23), PFNX: 12.45 (+0.29), HSP: 87.35 (unch)
Insider Trading Alert - EXLS, COB And ABAX Traded By Insiders
at The Street - Wed Feb 11, 9:15AM CST
Stocks with insider trader activity include EXLS, COB and ABAX
EXLS: 31.34 (-0.05), ABAX: 60.93 (+0.65), COB: 10.25 (+0.18)
CareFusion to Distribute Breas Medical's Vivo Ventilators in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:28PM CST
CareFusion Corp (CFN) recently announced the signing of an exclusive distribution agreement with Breas Medical for the latter's Vivo line of ventilation equipment.
BDX: 143.71 (+0.72), ABAX: 60.93 (+0.65), CFN: 59.81 (+0.01), VASC: 26.44 (+0.79)
14.1% Return Seen to Date on SmarTrend Abaxis Call (ABAX)
Comtex SmarTrend(R) - Mon Feb 09, 4:56PM CST
SmarTrend identified an Uptrend for Abaxis (NASDAQ:ABAX) on October 31st, 2014 at $52.37. In approximately 3 months, Abaxis has returned 14.07% as of today's recent price of $59.74.
ABAX: 60.93 (+0.65)
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Abaxis Earnings - Recent Correction Offers Buying Opportunity
Andy Batts - at Seeking Alpha - Sat Feb 07, 1:25PM CST
ABAX: 60.93 (+0.65)
CareFusion Q2 Earnings & Revenues Top Estimates, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:22AM CST
CareFusion Corporation's (CFN) second-quarter fiscal 2015 EPS surged nearly 83.3% on a year-over-year basis driven by strong revenue growth.
ICUI: 88.98 (+0.42), BDX: 143.71 (+0.72), ABAX: 60.93 (+0.65), CFN: 59.81 (+0.01)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
Boston Scientific Tops Q4 Earnings, Revenues Miss Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 9:27AM CST
Boston Scientific (BSX) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 22 cents in the fourth quarter of 2014.
BSX: 14.98 (+0.24), ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65)
Haemonetics Q3 Earnings Top Estimates, Drop Y/Y; Stock Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 9:00AM CST
Although Haemonetics' (HAE) earnings topped the Zacks Consensus Estimate, it reflected a significant slash year-over-year. With the bleak performance of blood center as well as hospital disposable businesses, the top line too failed to meet our expectation
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65), HAE: 42.94 (-0.59)
U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations
M2 - Mon Feb 02, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dl4jfq/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations" report to their offering. This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. U.S. Glucose Testing Markets 2014 analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Testing Technology Platforms and Consumable Products 6. Glucose Testing Devices on the Market 7. Business Trends in Glucose Testing 8. Technology Trends 9. Company Profiles - Click the link below to view the full list of companies featured in this extensive report - Abaxis, Inc. - Abbott Laboratories - AgaMatrix - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - BioTex - Calisto Medical - Cambridge Sensors - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Echo Therapeutics - GlySens - GlySure Limited - Grove Instruments - Hainice Medical - HemoCue (a Quest Diagnostics company) - Johnson & Johnson - Luminous Medical - Medtronic - Nipro Corporation - Nova Biomedical - OrSense - Polymer Technology Systems - Radiometer Medical - Roche - 77 Elektronika Kft. - Siemens AG For more information visit http://www.researchandmarkets.com/research/dl..._s_glucose
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Global Hematology Analyzers and Reagents Market 2015-2019 with Abbott Laboratories, Beckman Coulter & Sysmex Dominating
M2 - Sat Jan 31, 12:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/txxl5m/global_hematology) has announced the addition of the "Global Hematology Analyzers and Reagents Market 2015-2019" report to their offering. The Global Hematology Analyzers and Reagents market to grow at a CAGR of 4.89% over the period 2014-2019 Hematology instruments are indispensable diagnostic tools and continue to sustain a strong position in the Global Healthcare industry. They include analyzers, flow cytometers, coagulation analyzers, and slide strainers. Hematology analyzers are computerized and highly specialized machines that determine the presence, count, and types of cellular elements in a blood sample for disease detection and monitoring. They are also used to determine non-cellular parameters of the blood such as hemoglobin and hematocrit. Samples of blood can be processed alone, in batches, or continuously in a hematology analyzer. Hematology reagents are used in conjunction with the analyzers. One key trend upcoming in this market is the increase in use of automated hematology analyzers. Automated analyzers enable faster processing of samples and generate results in less time. Automated hematology analyzers are also more efficient and cost-effective. According to the report, one of the main drivers of this market is the increasing aging population worldwide. The elderly are susceptible to many age-related diseases and require access to medical therapies depending on the diagnostic test results. Hematology analyzers offer great hope for the early detection of diseases. Further, the report states that one of the major challenges in the market is the high cost of the hematology analyzers. Hematology analyzers are expensive because of their portability and automated features. Small vendors are unable to capitalize on the investment on high cost automated hematology analyzers. Key Vendors - Abbott Laboratories - Beckman Coulter - Sysmex Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Companies Mentioned - Abbott Laboratories - Beckman Coulter - Sysmex - Abaxis - Boule Diagnostics - Drucker Diagnostics - HORIBA - Mindray Medical International - Nihon Kohden - Roche Diagnostics - Siemens Healthcare Diagnostics For more information visit http://www.researchandmarkets.com/research/tx...hematology
ABT: 46.09 (+0.87), ABAX: 60.93 (+0.65), MR: 27.19 (+0.15)
Abaxis (ABAX) Beats Q3 Earnings, Revenues; Margin Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:50PM CST
Based on an encouraging top line, Abaxis' (ABAX) fiscal third-quarter gross profit rose 51% to $29.2 million
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), ABAX: 60.93 (+0.65), HSIC: 143.18 (+0.72)
Abaxis (ABAX) Is Today's Strong And Under The Radar Stock
at The Street - Fri Jan 30, 8:45AM CST
Trade-Ideas LLC identified Abaxis (ABAX) as a strong and under the radar candidate
ABAX: 60.93 (+0.65)
Medtronic's Reveal Cardiac Monitor: Key to AF Detection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 2:15PM CST
The incremental cost-effectiveness ratio (ICER) associated with the utilization of Medtronic's (MDT) Reveal XT ICM came well within the cost-effectiveness range supported by the United Kingdom's National Institute of Clinical Excellence.
CSII: 35.69 (+0.17), MDT: 75.26 (+0.33), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65)
Phibro Animal Health (PAHC) in Focus: Stock Jumps 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 8:18AM CST
Phibro Animal Health Corporation (PAHC) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
ABAX: 60.93 (+0.65), PAHC: 30.85 (+0.36)
Why Abaxis (ABAX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 7:34AM CST
Abaxis in the Medical Products space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
ABAX: 60.93 (+0.65)
St. Jude Medical HALO US IDE Trial Tests 15mm Heart Valves - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:13PM CST
Global medical devices company, St. Jude Medical (STJ), recently launched the HALO U.S. IDE Trial.
CSII: 35.69 (+0.17), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65), STJ: 67.48 (+0.65)
ResMed Targets Expansion in HME Market, Acquires Jaysec - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 3:09PM CST
Through Jaysec's acquisition, ResMed (RMD) will experience reduced administrative burden owing to the self-serve software portal specifically designed for HME providers.
CSII: 35.69 (+0.17), PAHC: 30.85 (+0.36), ABAX: 60.93 (+0.65), RMD: 66.25 (+0.79)
Pfenex Up on Lucentis Biosimilar Collaboration with Hospira - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 11:30AM CST
Hospira (HSP) inked a deal with Pfenex Inc. (PFNX) for the development and global commercialization of PF582, a biosimilar of Lucentis (eye treatment).
ABAX: 60.93 (+0.65), PFE: 34.64 (-0.23), PFNX: 12.45 (+0.29), HSP: 87.35 (unch)
Insider Trading Alert - EXLS, COB And ABAX Traded By Insiders
at The Street - Wed Feb 11, 9:15AM CST
Stocks with insider trader activity include EXLS, COB and ABAX
EXLS: 31.34 (-0.05), ABAX: 60.93 (+0.65), COB: 10.25 (+0.18)
CareFusion to Distribute Breas Medical's Vivo Ventilators in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 1:28PM CST
CareFusion Corp (CFN) recently announced the signing of an exclusive distribution agreement with Breas Medical for the latter's Vivo line of ventilation equipment.
BDX: 143.71 (+0.72), ABAX: 60.93 (+0.65), CFN: 59.81 (+0.01), VASC: 26.44 (+0.79)
14.1% Return Seen to Date on SmarTrend Abaxis Call (ABAX)
Comtex SmarTrend(R) - Mon Feb 09, 4:56PM CST
SmarTrend identified an Uptrend for Abaxis (NASDAQ:ABAX) on October 31st, 2014 at $52.37. In approximately 3 months, Abaxis has returned 14.07% as of today's recent price of $59.74.
ABAX: 60.93 (+0.65)
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Abaxis Earnings - Recent Correction Offers Buying Opportunity
Andy Batts - at Seeking Alpha - Sat Feb 07, 1:25PM CST
ABAX: 60.93 (+0.65)
CareFusion Q2 Earnings & Revenues Top Estimates, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:22AM CST
CareFusion Corporation's (CFN) second-quarter fiscal 2015 EPS surged nearly 83.3% on a year-over-year basis driven by strong revenue growth.
ICUI: 88.98 (+0.42), BDX: 143.71 (+0.72), ABAX: 60.93 (+0.65), CFN: 59.81 (+0.01)
Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets
M2 - Thu Feb 05, 2:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/2mh8jd/point_of_care) has announced the addition of the "Global Point of Care Diagnostic Testing Markets Analysis 2014: Detailed Analysis of 25 Individual Country Markets" report to their offering. The report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Selection of 30 Companies: Click the link below to view the full extensive list featured in this report - Abaxis, Inc. - Abbott Laboratories - Acrongenomics - AgaMatrix - Augurix Diagnostics Ltd. - Axis-Shield Plc (Alere) - Axxin - Bayer Corp - Chembio Diagnostic, Inc. - Home Diagnostics (Nipro Diagnostics) - Medix Biochemica - MedMira Laboratories - MELA Sciences (Formerly Electro-Optical Sciences) - A. Menarini Diagnostics - Meretek Diagnostics Group - Nexus/ITC - Nova Biomedical - OraSure Technologies, Inc. - Orion Diagnostica - Polymedco, Inc. - Polymer Technology Systems, Inc. - Prima Biomedical Company - QBC Diagnostics - Qualigen - Selfcare, Inc. - Shanghai Ruicare Medical Co., Ltd. - Shenzhen Fitconn Technology Co., Ltd. - Siemens AG - Siloam Biosciences, Inc. - V?samed, Inc. For more information visit http://www.researchandmarkets.com/research/2m...nt_of_care
ABT: 46.09 (+0.87), MELA: 1.55 (+0.09), ABAX: 60.93 (+0.65), OSUR: 8.13 (+0.06)
Boston Scientific Tops Q4 Earnings, Revenues Miss Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 9:27AM CST
Boston Scientific (BSX) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 22 cents in the fourth quarter of 2014.
BSX: 14.98 (+0.24), ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65)
Haemonetics Q3 Earnings Top Estimates, Drop Y/Y; Stock Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 9:00AM CST
Although Haemonetics' (HAE) earnings topped the Zacks Consensus Estimate, it reflected a significant slash year-over-year. With the bleak performance of blood center as well as hospital disposable businesses, the top line too failed to meet our expectation
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65), HAE: 42.94 (-0.59)
U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations
M2 - Mon Feb 02, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dl4jfq/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations" report to their offering. This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. U.S. Glucose Testing Markets 2014 analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Testing Technology Platforms and Consumable Products 6. Glucose Testing Devices on the Market 7. Business Trends in Glucose Testing 8. Technology Trends 9. Company Profiles - Click the link below to view the full list of companies featured in this extensive report - Abaxis, Inc. - Abbott Laboratories - AgaMatrix - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - BioTex - Calisto Medical - Cambridge Sensors - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Echo Therapeutics - GlySens - GlySure Limited - Grove Instruments - Hainice Medical - HemoCue (a Quest Diagnostics company) - Johnson & Johnson - Luminous Medical - Medtronic - Nipro Corporation - Nova Biomedical - OrSense - Polymer Technology Systems - Radiometer Medical - Roche - 77 Elektronika Kft. - Siemens AG For more information visit http://www.researchandmarkets.com/research/dl..._s_glucose
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Global Hematology Analyzers and Reagents Market 2015-2019 with Abbott Laboratories, Beckman Coulter & Sysmex Dominating
M2 - Sat Jan 31, 12:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/txxl5m/global_hematology) has announced the addition of the "Global Hematology Analyzers and Reagents Market 2015-2019" report to their offering. The Global Hematology Analyzers and Reagents market to grow at a CAGR of 4.89% over the period 2014-2019 Hematology instruments are indispensable diagnostic tools and continue to sustain a strong position in the Global Healthcare industry. They include analyzers, flow cytometers, coagulation analyzers, and slide strainers. Hematology analyzers are computerized and highly specialized machines that determine the presence, count, and types of cellular elements in a blood sample for disease detection and monitoring. They are also used to determine non-cellular parameters of the blood such as hemoglobin and hematocrit. Samples of blood can be processed alone, in batches, or continuously in a hematology analyzer. Hematology reagents are used in conjunction with the analyzers. One key trend upcoming in this market is the increase in use of automated hematology analyzers. Automated analyzers enable faster processing of samples and generate results in less time. Automated hematology analyzers are also more efficient and cost-effective. According to the report, one of the main drivers of this market is the increasing aging population worldwide. The elderly are susceptible to many age-related diseases and require access to medical therapies depending on the diagnostic test results. Hematology analyzers offer great hope for the early detection of diseases. Further, the report states that one of the major challenges in the market is the high cost of the hematology analyzers. Hematology analyzers are expensive because of their portability and automated features. Small vendors are unable to capitalize on the investment on high cost automated hematology analyzers. Key Vendors - Abbott Laboratories - Beckman Coulter - Sysmex Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis Companies Mentioned - Abbott Laboratories - Beckman Coulter - Sysmex - Abaxis - Boule Diagnostics - Drucker Diagnostics - HORIBA - Mindray Medical International - Nihon Kohden - Roche Diagnostics - Siemens Healthcare Diagnostics For more information visit http://www.researchandmarkets.com/research/tx...hematology
ABT: 46.09 (+0.87), ABAX: 60.93 (+0.65), MR: 27.19 (+0.15)
Abaxis (ABAX) Beats Q3 Earnings, Revenues; Margin Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:50PM CST
Based on an encouraging top line, Abaxis' (ABAX) fiscal third-quarter gross profit rose 51% to $29.2 million
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), ABAX: 60.93 (+0.65), HSIC: 143.18 (+0.72)
Abaxis (ABAX) Is Today's Strong And Under The Radar Stock
at The Street - Fri Jan 30, 8:45AM CST
Trade-Ideas LLC identified Abaxis (ABAX) as a strong and under the radar candidate
ABAX: 60.93 (+0.65)
